Helus Pharma has appointed Jill Conwell as chief people officer, effective immediately. The clinical-stage pharmaceutical company, which develops novel serotonergic agonists to address mental health conditions, stated that Conwell will help guide its talent strategy and organizational development as it advances clinical programs and prepares for its next phase of growth.
Conwell brings more than 20 years of leadership experience in the life sciences industry, with expertise in organizational strategy, talent development, corporate communications and investor relations. She has previously held senior leadership roles at Aclaris Therapeutics, Idera Pharmaceuticals and Shire Pharmaceuticals, where she helped build and scale organizations during periods of growth and pipeline advancement.
The appointment comes as Helus Pharma advances its clinical pipeline. The company is currently developing HLP003, a proprietary novel serotonergic agonist, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. This candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, also a proprietary novel serotonergic agonist, is in Phase 2 development for generalized anxiety disorder. The company has an extensive research portfolio of investigational novel serotonergic agonists.
Helus Pharma aims to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions through the development of synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's proprietary novel serotonergic agonists are intended to provide durable improvements in mental health.
This leadership appointment signals Helus Pharma's preparation for potential commercialization and scaling efforts should its clinical programs prove successful. The strategic focus on organizational development and talent acquisition is critical for pharmaceutical companies navigating late-stage clinical trials and regulatory processes. For more information about the company, visit https://www.helus.com.
The development of novel treatments for mental health conditions represents a significant area of medical need, with current treatments often providing inadequate relief for many patients. Helus Pharma's clinical progress, combined with strategic leadership appointments, highlights the ongoing innovation within the pharmaceutical sector aimed at improving mental health outcomes. The company operates in Canada, the United States, the United Kingdom and Ireland.
